Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

By D. Angiolillo, A. Fernández-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. Bass, M. Costa. Journal of the American College of Cardiology, 2007

1,016 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/e25cbfeed4c0f2f2eca7e8d851d80e0d3a57eae9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. U. Tantry
2. T. Pollin
3. Coleen Damcott
4. J. O’Connell
5. A. Parsa
6. N. Faraday
7. K. Ryan
8. Braxton D. Mitchell

Citations in the corpus

• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. (2011, neutral): “BMI, median (range) 31 (15-66) 31 (15-60) .”
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. (2009, background): “Variability in clopidogrel response is well established.(6-8) Patients treated with clopidogrel who demonstrate higher ex vivo platelet reactivity are at increased risk of ischemic events.”